BTI 320

Drug Profile

BTI 320

Alternative Names: BTI-320; PAZ-320

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston Therapeutics
  • Developer Advance Pharmaceutical Co Ltd; Boston Therapeutics
  • Class Antihyperglycaemics; Mannans
  • Mechanism of Action Alpha-glucosidase inhibitors; Amylase inhibitors; Carbohydrate metabolism inhibitors; Glucose modulators; Hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 06 Apr 2018 Boston Therapeutics receives patent allowance for BTI 320 composition of matter in European Union
  • 09 Jun 2017 Efficacy data from a phase II trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top